GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares




GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares

CHICAGO–(BUSINESS WIRE)–GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the “MS Lender”), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lender. Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.

J.P. Morgan, Citigroup and Morgan Stanley are acting as the lead joint book-running managers for the Offering. The Offering is expected to close on November 12, 2024, subject to customary closing conditions.

The GEHC Shares will be offered from time to time in one or more transactions on The Nasdaq Stock Market LLC, in the over-the-counter market or through negotiated transactions or otherwise at prices prevailing at the time of sale, at prices related to prevailing prices or at negotiated prices.

The Offering is being made pursuant to an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. A final prospectus supplement and accompanying prospectus describing the terms of the Offering will be filed with the SEC. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and accompanying prospectus relating to the Offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Forward‐Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain. The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Please also see the “Risk Factors” section of the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Contacts

Investor Relations:
Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

Media:
Jennifer Fox

+1-414-530-3027

jennifer.r.fox@gehealthcare.com

GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares




GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares

CHICAGO–(BUSINESS WIRE)–GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the “MS Lender”), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lender. Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.

J.P. Morgan, Citigroup and Morgan Stanley are acting as the lead joint book-running managers for the Offering.

The Company has filed an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this Offering. The Offering will be made only by means of a free writing prospectus, the prospectus and the accompanying prospectus supplement relating to the Offering. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the free writing prospectus, the prospectus and, when available, the accompanying prospectus supplement relating to the Offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Forward‐Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain. The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Please also see the “Risk Factors” section of the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Contacts

Investor Relations:
Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

Media:
Jennifer Fox

+1-414-530-3027

jennifer.r.fox@gehealthcare.com

Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman




Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman

STAAD, Switzerland–(BUSINESS WIRE)–Biosynth, a global supplier of critical raw materials and services to the life sciences industry, today announced that its Board of Directors has appointed Matt Gunnison as the company’s new Chief Executive Officer and a member of the Board of Directors, effective immediately. The Board has also appointed Kieran Murphy as Chairman, effective as of the same date.

Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growth and strengthened its position in the life sciences sector. Urs Spitz will remain a member of the Board of Directors.

“We are grateful to Urs for his significant contributions in shaping Biosynth into the innovative and thriving company it is today. We are now excited to welcome Matt as CEO, whose vision and extensive experience will be pivotal in leading the company through its next chapter,” said Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy.

“I am thrilled to join Biosynth at such an exciting time in its journey. The company has built a strong foundation under Urs’s leadership, and I look forward to working with the talented team to further accelerate our growth and innovation. Together, we will continue to deliver critical raw materials and services that drive advancements in the life sciences and make a real impact on global health outcomes,” said Matt Gunnison.

“It’s a privilege to be appointed Chairman of Biosynth. I am excited to work alongside Matt and the entire team as we chart the course for the company’s continued growth. Biosynth is at the forefront of innovation in the life sciences industry, and I am confident we have the right leadership and vision to drive our success forward,” said Kieran Murphy.

“I’m immensely proud of what Biosynth has accomplished. I would like to congratulate Matt and Kieran on their new roles and wish them, along with the whole Biosynth team, great success in the years ahead. I look forward to continuing to support them in my role on the Board as they lead Biosynth into this new chapter,” said Urs Spitz.

Matt currently serves as CEO of Gamma Biosciences, a life sciences investment platform that he co-founded with leading global investment firm KKR. He brings nearly two decades of experience in the healthcare and life sciences industries. At Gamma, Matt oversaw the acquisition and management of a portfolio of growth stage businesses serving the biopharmaceutical manufacturing industry. Prior to Gamma, he served in various positions at GE Healthcare, most recently as head of corporate development for the $19B division of General Electric Co. Matt holds a B.A. in Economics from Georgetown University and a J.D. from the University of Michigan.

Kieran currently serves as a senior advisor to KKR and will transition to Biosynth from Gamma Biosciences, where he has served as Chairman since 2022. He brings decades of corporate leadership and board experience in healthcare and life sciences, including as former President and CEO of GE Healthcare and GE Healthcare Life Sciences.

Joining Matt and Kieran, as Head of Corporate Development for Biosynth, is Eric Simpson, previously Vice President at Gamma Biosciences.

About Biosynth

Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Ampersand

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit Ampersandcapital.com or follow Ampersand on LinkedIn.

Contacts

Biosynth
Alannah Wheeler

+44 7984 525560 marketing@biosynth.com

KKR
FGS Global
Alastair Elwen/ Jack Shelley

+44 20 7251 3801/ +44 7917 886 576 KKR-Lon@FGSGlobal.com

Ampersand
Kathleen Toomey kpt@ampersandcapital.com

Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024




Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced its participation in upcoming investor conferences to take place in November 2024.

• Sensorion will participate in the Stifel Healthcare Conference, which will be held in New York, USA, on November 18-19, 2024. Sensorion’s management team will be present for one-to-one meetings on November 18, 2024.

• Sensorion will also participate in the LifeSci Capital and Sofinnova Partners Growth & Innovation Summit, to take place in London, UK, on November 18, 2024. Sensorion’s management team will be present for one-to-one meetings throughout the conference.

• Sensorion will also be attending the Jefferies London Healthcare Conference, in London, UK, on November 19-21, 2024. Sensorion’s management team will be present for one-to-one meetings throughout the conference.

If you would like to meet Sensorion’s management team, please contact us by email: ir.contact@sensorion-pharma.com

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, has completed in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Label: SENSORION

ISIN: FR0012596468

Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Contacts

Investor Relations
Noémie Djokovic, Investor Relations and Communication Associate

ir.contact@sensorion-pharma.com

Press Relations
Ulysse Communication

Bruno Arabian / 00 33(0)6 87 88 47 26

barabian@ulysse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54

nentz@ulysse-communication.com

Inocras and Summit Pharmaceuticals International Corporation Announce Collaboration Aim to Transform Clinical Genomics in Japan




Inocras and Summit Pharmaceuticals International Corporation Announce Collaboration Aim to Transform Clinical Genomics in Japan

SAN DIEGO–(BUSINESS WIRE)–Inocras Inc. (Head Office: 6330 Nancy Ridge Drive Suite 106
San Diego, CA 92121, President & CEO: Jehee Suh) (“Inocras”) and Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama) (“SPI”) signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionize healthcare in Japan by leveraging genomic data and bioinformatics to better understand and treat cancer and other genetic conditions.

WGS reads an individual’s entire genome, generating vast data. Inocras’ bioinformatics platform transforms this data into actionable clinical insights, enabling precise diagnoses support and personalized treatments. Inocras, a leader in whole-genome sequencing (WGS) and bioinformatics, has partnered with SPI to bring cutting-edge genomic solutions to the Japanese market. In particular, their proprietary technology (*) and bioinformatics pipeline are expected to provide valuable insights in genomic medicine.

(*) Proprietary technology that enables WGS using formalin-fixed paraffin-embedded (FFPE) samples, which are widely utilized in clinical settings.

Inocras and SPI will develop a business plan to integrate WGS into Japan’s healthcare system. This effort includes assessing market potential, developing operational models, and evaluating clinical impact. Input from key opinion leaders and other stakeholders will help shape future developments. Future plans include establishing a WGS lab and enhancing local bioinformatics capabilities.

“Inocras is excited to bring advanced WGS and bioinformatics to Japan, offering solutions no other commercial provider delivers here,” said Jehee Suh, CEO of Inocras. “With SPI, we are creating a pathway to improve patient care through data-driven innovation.”

“Japan is at a pivotal point in embracing genomic medicine, and this partnership with Inocras is perfectly timed to help accelerate that transformation,” said Katsuya Okuyama, CEO of SPI.

About Inocras Inc:

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing. The company offers its whole genome testing products, CancerVision and RareVision, and provides research services for pharmaceutical and biotechnology companies, as well as research organizations. These services are conducted through its CAP/CLIA-certified lab, powered by a proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com.

About Summit Pharmaceuticals International Corporation:

SPI provides high-quality, integrated products and services for the pharmaceutical industry, from research equipment and biological resources for drug discovery research, pharmaceutical licensing, and research partnership support, to the production of active pharmaceutical ingredients, intermediates for new drugs, generics, and biologics. Our parent company, Sumitomo Corporation, is one of the world’s leading global companies, with a network of 127 locations in 65 countries and 20 locations within Japan (as of April 1, 2024), offering a wide range of products and services.

Contacts

Inocras Inc.

PR (Sohee Cho)

Email: media@inocras.com

Summit Pharmaceuticals International Corporation

Research Acceleration Department BioSciences Group2 (Ryoko Shimada)

Tel: +81-3-5220-1520

Email: bioinfo@summitpharma.co.jp

Fusion Orthopedics, LLC Wins! Judgment Has Been Entered Against Extremity Medical LLC by USPTO




Fusion Orthopedics, LLC Wins! Judgment Has Been Entered Against Extremity Medical LLC by USPTO

MESA, Ariz.–(BUSINESS WIRE)–Fusion Orthopedics, LLC wins! Judgment has been entered against Extremity Medical LLC from the USPTO’s Patent Trial and Appeal Board (“PTAB”) through an inter partes review (“IPR”) of U.S. Patent No. 11,298,166 (‘166 patent) wherein the PTAB found 14 claims of the ‘166 patent are invalid and denied both of Extremity Medical, LLC’s motions to amend the claims of the ‘166 patent. As the record reflects, dependent claim 11 of the ‘166 patent is also invalid. As such, any frivolous efforts by Extremity Medical, LLC to continue to assert invalid claims will likely be held as bad faith and sanctionable.

Extremity Medical, LLC (“Extremity Medical”) allegedly filed the ‘166 patent in 2021 targeting the IntraLock, which launched in 2019, for the sole purpose of attempting to harass and extract an unreasonable settlement from Fusion Orthopedics, LLC (“Fusion Orthopedics”). Subsequently, Extremity Medical filed a bad faith patent infringement lawsuit on April 28th, 2023, allegedly to subdue Fusion Orthopedics’ explosive rise in the foot and ankle market. (See Case No. 22-CV-00723-GMS).

In Federal Court, Extremity Medical has aggressively sought to enforce invalid patent claims within the ‘166 Patent Family against Fusion Orthopedics, Zimmer Biomet, and Paragon 28. In the matter between Extremity Medical and Zimmer Biomet, Extremity Medical was sanctioned in the amount of $52,573.00 for Zimmer Biomet’s attorneys’ fees in pursuing frivolous patent infringement claims. Fusion Orthopedics will likely seek similar monetary relief at the appropriate time against Extremity Medical. (See Case No. 22-CV-00239-GBW).

Given this history, Fusion Orthopedics believes that baseless shakedown litigation is an accepted business practice of Extremity Medical under the leadership of Matthew Lyons, Extremity Medical’s CEO and Founder.

Fusion Orthopedics believes Extremity Medical has numerous invalid patents that they may assert against Fusion Orthopedics (E.g., U.S. Patent Nos. 8,303,589, 8,900,274, 9,364,271, 9,877,752, 10,751,097, “the ‘166 Patent Family”). This IPR is likely the first of many to be successfully pursued against Extremity Medical’s ‘166 Patent Family by Fusion Orthopedics.

As a matter of good public policy, Fusion Orthopedics is deeply committed to combating any such abusive and bad faith legal tactics by Extremity Medical, Matthew Lyons, and others. It is Fusion Orthopedics’ practice to recognize and respect valid intellectual property of others. Fusion Orthopedics is undeterred in its pursuit as an innovator in technology related to foot and ankle orthopedic devices. Fusion Orthopedics stands by the disruptive IntraLock product, especially when wrongfully accused of patent infringement.

Contacts

Media Contact:
Corby Vowell, Esq

(817) 313-9548

corby@vowelllawfirm.com

Vitrian Closes on $50M Initial Investment into Biomanufacturing Capacity in Central Ohio and Launches Partnership with AmplifyBio




Vitrian Closes on $50M Initial Investment into Biomanufacturing Capacity in Central Ohio and Launches Partnership with AmplifyBio

BETHESDA, Md. & WEST JEFFERSON, Ohio–(BUSINESS WIRE)–Vitrian, the leading end-to-end provider of investment capital and capacity building services for biomanufacturing, announced today that it closed a $50 million investment, with ability to scale to $65 million, into AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio as a first step of a larger commitment to support biomanufacturing in Central Ohio. AmplifyBio is a leading advanced therapy CRO and CDMO offering a full range of drug development and manufacturing services.

Located in the heart of Central Ohio’s advanced manufacturing corridor, adjacent to Intel’s $20B Ohio One semiconductor mega-fab facility and Amgen’s $360 million biomanufacturing plant, the 350,000 square-foot AMEC site is home to AmplifyBio’s multi-modality process development and quality control labs and GMP manufacturing suites.

“We are very excited to make our first investment in Ohio and launch a wider partnership with AmplifyBio. We have been impressed by the creativity and progressive thinking of the AmplifyBio team and look forward to further collaborations. The infrastructure investment from state and local government, favorable workforce development environment, and support of important institutional anchors in the Columbus area aligns well with our investment and partnership thesis,” said Scott Nudelman, Co-Founder and Managing Principal at Vitrian.

“We chose to partner with Vitrian based on the alignment of our strategic goals for our manufacturing site, and we are hopeful this is the first of many things we can do together.” said J. Kelly Ganjei, CEO of AmplifyBio. “As we execute our strategy to enable flexible advanced therapy manufacturing and ancillary services, we believe Vitrian will be a great partner.”

About Vitrian

Vitrian is the first fully integrated company dedicated exclusively to providing end-to-end solutions for biomanufacturing and cGMP facilities. Its mission is to foster the next generation of drugs and therapies through facility real estate investment/development, improving the capitalization process, and building capacity for future growth through civic engagement and workforce development. Vitrian is actively engaged in training/capacity building for the entry-level biomanufacturing workforce across its primary markets. Its current engagements span modalities across advanced therapeutics, aseptic fill/finish, synthetic biology, and radiopharma with active projects in 6+ US markets. Visit www.vitrian.com.

About AmplifyBio

AmplifyBio is a contract research and manufacturing organization founded on the principle that all development and scale-up of advanced modality drugs should be done with commercial goals in mind. It was launched out of Battelle in 2021, with an initial offering of industry-leading preclinical toxicology, safety, and pharmacology testing in an agile environment with analytics capabilities that serve the dynamic safety requirements of modern modalities. Since then, AmplifyBio has developed drug characterization and optimization service capabilities and expertise based on the closely held principle that rich characterization, optimization, and data integrity are the keys to reproducibility and scale-up. The company then added GMP manufacturing, completing its concept-to-commercial service offering for the development of advanced therapies.

Contacts

Marty Schnider

marty@vitrian.com

Kimberly LaPointe

klapointe@amplify-bio.com

e4shieldtm, the New Frontline Weapon in the War Against Viruses Will Be at MEDICA




e4shieldtm, the New Frontline Weapon in the War Against Viruses Will Be at MEDICA

The first technology in the world to use electromagnetic waves in order to inactivate viruses (Covid, influenza, avian flu and swine flu) with an efficacy rate of over 90% will be the star of the Düsseldorf trade show from 11^th to 14^th November, a point of reference event for technology and healthcare

DÜSSELDORF, Germany–(BUSINESS WIRE)–e4life, a joint venture resulting from the partnership between two global giants such as the ELT Group, world leader in Electronic Defence, and Lendlease, specialists in large-scale urban regeneration projects, will be bringing e4shield^tm technology to MEDICA. This is the point of reference trade show for the technology and healthcare sector and will be held in Düsseldorf from 11^th to 14^th November.

e4Life is aiming to be a standard bearer of innovation in health protection as seen from a “one health” point of view, promoting safety through cutting-edge technological solutions and a constant commitment to global well-being.

“The health of the planet is unavoidably interconnected with all the other life forms that live on it. This is the core of the ‘One Health’ concept, and one which reminds us that human, animal and environmental health are closely interlinked and cannot be treated as separate watertight compartments” explains e4life CEO Vincenzo Pompa. “e4life’s vision focuses on a future in which every individual can enjoy a social lifestyle, interacting in safe spaces without worries. This is why e4life is at the forefront in researching and developing technologically advanced products that are effective in inactivating viruses, with the aim of reducing risks in every space in which people and animals live”.

This is the context which saw the development of e4shield^tm, the innovative technology that uses electromagnetic waves to neutralize not only Covid and influenza viruses with a certified efficacy of over 90%, but also those of avian flu and swine flu present in the air. This solution is the only one of its kind worldwide and although it is based on military technology, it is harmless to humans and animals, having currently certified for marketing in Europe, Australia, Japan, Singapore, Saudi Arabia, the UAE, Morocco and Egypt.

The technology behind e4shield^tm was developed during the Covid period thanks to the initiative of the ELT Group which decided to investigate in greater depth the use of electromagnetic fields in the inactivation of viruses. Based on research obtained by Taiwanese scientists published in the Nature Scientific Report journal, the company achieved its first results by testing different frequencies of electromagnetic waves initially on Covid and then on other Corona Viruses.

The technology does not use either chemical agents or filter materials, but is based on the transmission of microwaves. Through a specific combination of frequency and power, these act on the balance between the internal positive charges of the virus and the negative charges present in the capsid or outer shell, giving rise to a “resonance” phenomenon that destroys the external envelope of the virus and effectively inhibiting the power of viruses to spread and transmit from one individual to another.

e4shield^tm can boast numerous validations in a wide range of different scientific laboratories. As a matter of fact, it has been subjected to rigorous scientific tests and verified by the Celio Military Hospital, the independent ViroStatics institute and two studies published in the Viruses and European Society of Medicine journals (Source: Esmed.org), an association of doctors, researchers and professionals from all over the world united by the goal of promoting health globally.

In addition, e4shield^tm has been the subject of a test campaign at the University of Milan (Italy) Department of Biomedical and Clinical Sciences. As part of this procedure, a bioaerosol system was recreated in a controlled laboratory environment in which SARS-CoV-2 viruses and those representing seasonal influenza (H1N1) were exposed to radiation generated by the e4shield device, which uses SRET (Structure Resonant Energy Transfer) phenomenology. The results obtained confirm those already found in previous test campaigns, i.e. a replicable efficacy of close to 90%.

The JRC – HERA technological study by the European Commission’s Joint Research Centre (JRC) includes this technology among that currently capable of guaranteeing an increase in air quality in indoor environments.

One of the distinctive features of e4shield^tm technology is the fact that its targeted action allows it to be calibrated against specific pathogens. Its current efficacy against human respiratory viruses is certified against Covid, including variants, and seasonal flu with an efficacy of over 95%, but its technology is constantly evolving and adaptable to an ever-increasing number of viruses and, in the near future, also to bacteria. Updates in terms of new frequencies effective against additional viruses can be downloaded directly from the e4life app available for Android and iOS Apple.

There are two versions of e4life on the market: e4life personal (a portable version) and e4life ambient (a fixed version designed to be installed on the ceilings or walls of a wide range of different environments).

Last but not least, 4life has recently presented 4life FARM, a device dedicated to livestock farms and designed to combat viral diseases such as avian flu and swine flu which pose a threat to chicken, turkey and pig farms. The device is based on the same e4shield technology, which emits electromagnetic waves at specific frequencies effective against this new family of viruses. As with devices intended for human use, e4life FARM also neutralizes over 90% of the viral load present in the air, including droplets up to 10 microns, and it does so virtually in real time thanks to the speed of light at which the waves spread.

Contacts

mauro.perego@elettrapr.it – +393938188596

Excipients in Pharmaceuticals Markets to 2029, with Focus on Leading Players ADM, Asahi Kasei, Ashland, BASF, Croda International, Evonik Industries, Ingredion, Kerry Group and Roquette Freres – ResearchAndMarkets.com




Excipients in Pharmaceuticals Markets to 2029, with Focus on Leading Players ADM, Asahi Kasei, Ashland, BASF, Croda International, Evonik Industries, Ingredion, Kerry Group and Roquette Freres – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Excipients in Pharmaceuticals: Global Markets to 2029” report has been added to ResearchAndMarkets.com’s offering.

The Excipients in Pharmaceuticals Market was valued at USD 9.7 billion in 2024, and is expected to reach USD 12.4 billion by 2029, rising at a CAGR of 5.10%.

This report provides a comprehensive summary of pharmaceutical excipients, along with a discussion of the competitive landscape and profiles of key market players that highlight revenues, product portfolios, and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities.

This research study discusses historical, current and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors and exporters will find useful information about market developments and trends.

The report segments the market by three product types: organic, inorganic or water that meets the standards of the U.S. Pharmacopeia (USP). Regional and country-level market analysis is provided for all the major segments.

The market is divided into segments as follows:

By excipient material type:

• Organic
• Inorganic
• USP water

By organic type:

• Carbohydrates
• Petrochemicals
• Oleochemicals
• Proteins
• Other organic excipients

By inorganic type:

• Calcium salts
• Halites
• Metal oxides
• Silicates
• Other inorganic excipients

By dosage form:

• Solid dosage form
• Liquid dosage form
• Semisolid dosage form
• Other dosage forms

By administration route:

• Oral
• Injectable
• Topical
• Advanced drug delivery

By end user:

• Pharmaceutical companies
• Contract formulators
• Research institutes
• Other end users

For each area, for the base year of 2023, the analyst identified the current products in the market as well as market drivers; measured the current market size; quantified current company market shares; and made forecasts for 2029.

The report includes:

• 73 data tables and 33 additional tables
• An overview of the global market for excipients in pharmaceuticals industry
• Analysis of global market trends, featuring historical revenue data from 2021 to 2023, estimated figures for 2024, and projected CAGRs through 2029
• Evaluation of the current market’s size and revenue growth prospects, along with a market share analysis by material, product type, dosage form, route of administration, end user and region
• A look at the innovations, technological advances, clinical trials, and recent product launches
• Analysis of the industry’s regulatory framework and policies
• A discussion of ESG challenges and ESG practices in the industry
• An analysis of the key companies’ market shares, proprietary technologies, strategic alliances and patents
• Profiles of the leading players in the excipients in pharmaceuticals market including ADM, BASF, Roquette Freres, Ashland Global, and Croda International.

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Role of Excipients in Pharmaceuticals
• Functions of Excipients

Chapter 3 Market Dynamics

• Market Drivers
  • Increasing Pharmaceutical and Biopharmaceutical Consumption
  • Increasing Demand for Functional Excipients
  • Increasing Demand for Novel Excipients
  • Instant Sourcing of Excipients
• Market Restraints
  • High Development Costs
  • Lack of Independent Regulatory Body for Novel Excipients
  • Stringent Pharmaceutical Regulations
• Market Opportunities
  • Growing Demand for Biologics, Biosimilars and Specialty Drugs
• Market Challenges
  • Supply Chain Disruptions

Chapter 4 Emerging Technologies and Developments

• 3D Printing in Drug Formulations
• AI in Excipient Selection
• Novel Excipients
• Clinical Trials
• Selected Trials

Chapter 5 Global Market for Pharmaceutical Excipients

• Segmentation Breakdown
  • Market Breakdown by Material Type
  • Organic Excipients Market, by Type
  • Market for Inorganic Excipients, by Type
  • Market for USP Water, by Type
  • Market Breakdown by Dosage Form
  • Market Breakdown by Route of Administration
  • Market Breakdown by End User
  • Market Breakdown by Region
  • Market Breakdown by Product
• Regional and Country-level Markets for Organic Excipients
• Regional and Country-level Markets for Inorganic Excipients

Chapter 6 Competitive Intelligence

• Industry Scenario
• Company Shares
• Competitive Landscape

Chapter 7 Sustainability in the Market for Pharmaceutical Excipients: An ESG Perspective

• Introduction to ESG
• Concluding Remarks

Company Profiles

• ADM
• Asahi Kasei Corp.
• Ashland
• BASF
• Croda International
• Evonik Industries
• Ingredion
• Kerry Group
• Roquette Freres

For more information about this report visit https://www.researchandmarkets.com/r/7rwptq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK




Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK

• New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore designed to:
  • Advance biomedical research and translate discoveries for improved patient care
  • Improve health outcomes by targeting novel genomic and epigenomic discoveries in cancer, human genetic disease and infectious disease
• Initial programme: creation of an ‘early warning system’ for future pandemics across as many as 30 NHS sites to support improved biosecurity nationwide
• Oxford Nanopore’s high-performance genomics technology to provide richer genomic data, faster, more accessibly and more affordably

OXFORD, England–(BUSINESS WIRE)–Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore, to support the government’s vision to build an NHS “fit for the future” by enabling genomics-based translational research and accelerating the development and adoption of Oxford Nanopore’s ground-breaking genomics technology in the NHS.

By utilising Oxford Nanopore’s richer genomic insights, rapid, scalable and affordable sequencing technology, the initiative aims to deliver transformative improvements in patient care and foster economic growth in the UK’s thriving life sciences sector.

Oxford Nanopore CEO Gordon Sanghera, commented:

“The UK has a remarkable genomics ecosystem, and we are delighted to be innovating more collaboratively through this partnership. Genomics England and UK Biobank have led the way in scaling genomics discovery and translating these advances into patient impact. NHS England, through its Networks of Excellence and advancements developed by the Genomic Laboratory Hubs (GLHs), has been instrumental in adopting these innovations into national healthcare strategies. By working alongside our partners on shared goals of improved patient outcomes – whether in cancer, human genetic disease or infectious disease – we believe we can deploy our unique DNA/RNA sequencing technology in ways that are most impactful for the people of the UK.”

Health and Social Care Secretary Wes Streeting, commented:

“If we fail to prepare, we should prepare to fail. Our NHS was already on its knees when the pandemic struck, and it was hit harder than any other comparable healthcare system.

“We cannot let history repeat itself. That’s why this historic partnership with Oxford Nanopore will ensure our world-leading scientists have the latest information on emerging threats at their fingertips.

“As we embrace the technological revolution, our 10 Year Health Plan will shift the NHS away from analogue to digital, saving countless more lives.”

Science and Technology Secretary Peter Kyle, commented:

“During the Covid pandemic we saw the power of the UK life sciences sector very clearly – from the Oxford-Astra Zeneca vaccine that saved so many lives, through to operating one of the world’s most effective Covid surveillance systems, which spotted several emerging variants of the disease.

“This partnership will build on that expertise to monitor emerging diseases as they arise, putting our scientists and decision-makers one-step ahead and providing the information they need to make informed decisions.

“Together with the ability to better diagnose cancers and rare diseases, we are leveraging UK life sciences to protect the public and ultimately save lives.”

Professor Susan Hopkins, Chief Medical Advisor at UK Health Security Agency, commented:

“Early detection is absolutely crucial in enabling us to respond effectively to any emerging pathogen. The UK already has a wealth of expertise in genomic surveillance, and this programme will build on that expertise and enable us to bring our resources and capability to tackle developing threats at greater speed. Enhancing the capacity for the NHS to determine new and emerging pathogens causing severe acute respiratory infections will improve the detection and emergence of infections.

“As part of the 100 days mission, this will enable the development of effective diagnostics for novel pathogens and enhance our pandemic preparedness.”

Professor Ian Abbs, Chief Executive of Guy’s and St Thomas’ NHS Foundation Trust, commented:

“We’ve been working on the respiratory metagenomics programme for over four years and have clearly seen the benefit to our patients. It’s a momentous day now that we can ensure other hospitals, and more patients, can also benefit from faster and more accurate treatment for severe respiratory conditions thanks to new genomic technology.”

Advancing the understanding of genomics, for future disease prevention and personalised medicine

Oxford Nanopore’s partnership with Genomics England and UK Biobank is aimed at translating research-based discoveries from the lab into clinical settings, benefiting UK healthcare. Priority areas include cancer, where genomic insights (the analysis of DNA) can help identify personalised treatment options and enhance early detection, and rare disease characterisation, where information-rich genomic and epigenetic analysis – changes to DNA that contribute to disease – can improve diagnosis and inform targeted therapies. This partnership presents a further opportunity to collaborate on broader emerging applications, which in the future could include newborn screening, where genomics can enable early identification of genetic disorders for prompt intervention, and pharmacogenomics, where genetic insights guide safer and more effective medication choices tailored to an individual’s genetic profile.

Creating a world-first pathogen surveillance system in the NHS

As a key part of the partnership, the UK will establish the first real-time, pathogen-agnostic biosurveillance system across as many as 30 hospitals in NHS England—a crucial early warning framework to detect and respond to emerging pandemics and biological threats. Building on successful NHS England Network of Excellence pilots led by Guy’s and St Thomas’ NHS Foundation Trust (GSTT), this system will expand the NHS Respiratory Metagenomics programme to enable rapid pathogen identification across the UK. This data will be provided by the NHS to the UK Health and Security Agency, allowing potentially quicker decisions on emerging diseases to be taken and bolstering national biosecurity as set forth in the UK Biological Security Strategy. This project is expected to start in 2025 and will continue over multiple years.

In addition to providing biosecurity capabilities, the expanded respiratory metagenomics programme will deploy Oxford Nanopore’s sequencing technology to support infectious disease management in the critical care setting. This rollout is designed to provide a groundbreaking, six-hour timeline for fully characterising respiratory diseases including drug (antimicrobial) resistance, an essential leap forward in patient care. By rapidly transitioning NHS diagnostics from analogue to digital, the programme’s goal is to enable quicker, targeted care for patients and reduce hospital strain, advancing the ambitions set out in the Government’s 10-Year Health Plan.

Translating genomics into enhanced NHS patient care

The integration of Oxford Nanopore’s innovative sequencing technology will enable the NHS to explore further this technology to characterise diseases including cancer and rare genetic conditions with greater speed and precision. With potential for collaborative development of rapid and improved diagnostic tools, Oxford Nanopore’s technology has the potential to enable patients across the NHS to benefit from earlier, more accurate disease detection and treatment pathways.

Driving economic growth and workforce development in life sciences

This work will not only enhance patient outcomes but also position the UK as a global leader in genomic research and innovation, further strengthening the nation’s biosecurity and healthcare resilience. By accelerating pathways for life sciences innovation into the NHS through globally recognised research programmes, this collaboration enhances the UK’s position as a global biotechnology hub, supporting economic growth and creating high-value jobs in the life sciences ecosystem. As part of this initiative, NHS staff and researchers will gain access to relevant training and support to advance a skilled workforce ready to harness the potential of genomics and personalised medicine.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 125 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

For more, visit: https://nanoporetech.com/
For images, visit: https://nanoporetech.com/about/for-the-media

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as “aim”, “plan”, “expect”, “intend”, “anticipate”, “believe”, “estimate”, “target”, and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, delays or challenges in manufacturing or delivering of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance or applied uses of our products. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

Contacts

media@nanoporetech.com